
BerGenBio Investor Relations Material
Latest events

M&A Announcement
BerGenBio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BerGenBio
Access all reports
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, focused on developing innovative therapies for aggressive diseases such as cancer and severe respiratory infections. The company specializes in AXL kinase inhibitors, with its lead product, Bemcentinib, currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and severe respiratory conditions. Another key asset, Tilvestamab, is a monoclonal antibody targeting AXL, being investigated for the treatment of ovarian cancer. BerGenBio is leveraging its expertise in AXL biology to create treatments that can potentially improve outcomes in diseases characterized by drug resistance and immune evasion. The company's strategy includes partnerships with clinical sites and biopharma firms to advance its drug pipeline. The company is headquartered in Bergen, Norway, and its shares are traded on the Oslo Stock Exchange.
Key slides for BerGenBio


Q2 2024
BerGenBio


M&A Announcement
BerGenBio
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BGBIO
Country
🇳🇴 Norway